Bupropion/naltrexone
Bupropion/naltrexone has been studied in 8 papers since 2024: 3 observational studies in people, 5 reviews; 4 in the past year. The newest paper, Jun 8, 2026: “Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists”.
8 papers study it1 findingUpdated
See all 8 papers on bupropion/naltrexone
- Humans3
What did studies of bupropion/naltrexone find?
1Studies of bupropion/naltrexone measured one outcome, obesity.
Obesity
downin humans1
1 study
Obesity
downin humans1
Bupropion/naltrexone decreases obesity in humans (strong recommendation).
“Strong recommendations were made for bupropion-naltrexone, semaglutide, tirzepatide, and setmelanotide, with moderate-certainty evidence.”
Reviewstrong recommendation
Obesity pillars
Latest
4 papers in 12 monthsDiabetes, Obesity & Metabolism
Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists
Cohort study of 68,536 peopleObesity
Ophthalmology Retina
Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies
Cohort study of 60,336 peopleAge-related macular degeneration
AHA Scientific Sessions 2025 Abstract
Real-World Effectiveness of GLP-1 Receptor Agonists on Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
Cohort study of 107,252 peopleGLP-1 receptor agonists
Archives of Endocrinology and Metabolism
Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
ReviewObesity